Navigation Links
Fox Chase Cancer Center Publishes Clinical Outcomes for Patient Use

PHILADELPHIA, Jan. 31, 2011 /PRNewswire/ -- Fox Chase Cancer Center, one of the nation's leading cancer research and treatment institutions, today announced the posting of clinical outcomes data to its website as a tool to assist newly-diagnosed patients in deciding where to seek cancer care.  This initiative follows on a survey Fox Chase commissioned in the fall of 2010, in which non-diagnosed adults ranked success rates as the factor that would be the most important in choosing a hospital if they were told that they or a family member required cancer treatment.

"We are committed to helping the public become more informed when making decisions about their health care," said Michael V. Seiden, M.D., Ph.D., president and CEO of Fox Chase Cancer Center. "While individual outcomes cannot be predicted, we hope this data will enable patients to make choices that are right for them, ensuring that they receive the best care possible."

While the movement toward greater medical transparency and patient empowerment grows nationally, only a handful of cancer institutions currently publish outcomes data, as measured by survival rates.  The figures Fox Chase has released describe five-year survival rates for patients diagnosed at the different stages of breast, colorectal, lung, and prostate cancers, the most common cancers in the United States.  These numbers are charted on Fox Chase's website in comparison to patient survival data from both small and large community hospitals across the country, using statistics from the National Cancer Data Base (NCDB), maintained by the American College of Surgeons.

"In these charts, people will see that patients receiving care at Fox Chase Cancer Center have superior outcomes compared to individuals treated for the major cancers in community hospitals," Seiden said. "We have always believed that our singular focus on understanding, preventing, and treating cancer leads to a higher overall standard of care, and the figures, on the whole, bear that out."

One of the main reasons for the distinction, Seiden says, lies in Fox Chase's patient volume and its exclusive focus on cancer.  Fox Chase, one of only a few dozen National Cancer Institute-designated Comprehensive Cancer Centers in the country, treats more than 32,000 oncology patients a year, including 7,600 new patients, and has active research and clinical trials programs that benefit patients from across the region. Through its Partners program with community-based hospitals in Pennsylvania and New Jersey, Fox Chase promotes the timely translation of research findings to ensure patients have access to the latest advances in cancer care and treatment.

"We know that our patients aren't just numbers, and we show it in the personal care that our oncologists and nursing staff deliver every day," said Dr. Seiden.  "But we believe that where patients first seek care can greatly influence their outcomes, and you can see some of those differences when comparing the outcomes of an institution such as Fox Chase, which has a sole focus on cancer care, informed by in-house research and clinical experience."

The Fox Chase commissioned survey from the fall of 2010, which included 406 non-diagnosed adults, was conducted by Kesselman Research and Strategic Planning.  The survey found that the most important factors when choosing a hospital for cancer care included high success rates, availability of the latest advances in cancer treatment, ability to handle the most complex cases, and individualized tailored targeted treatments.

To view the clinical outcomes that Fox Chase Cancer Center has published, visit

About Fox Chase Cancer CenterFox Chase Cancer Center is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet status for excellence three consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach.  For more information, visit Fox Chase's website at or call 1-888-FOX CHASE (1-888-369-2427).Contact:

Diana Quattrone215-728-7784Cell –

SOURCE Fox Chase Cancer Center
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Novogen and Marshall Edwards Sign Asset Purchase Agreement
2. Sequenom Announces Exercise in Full of Underwriters Option to Purchase Additional Shares
3. TPC Group Announces Commencement of Dutch Auction Tender Offer to Repurchase for Cash up to $130 Million in Common Stock
4. Quest Diagnostics Increases Share Repurchase Authority By $250 Million
5. Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants
6. China Cord Blood Corporation Updates Status Regarding Share Repurchase Program
7. Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses
8. Fox Chase Celebrates the 50th Anniversary of the Discovery of the Philadelphia Chromosome
9. Cole-Parmer Announces Automatic Tax Calculation for Online Purchases
10. BioMed Realty, L.P. Completes $180 Million Offering of 3.75% Exchangeable Senior Notes, Including Full Exercise of Initial Purchasers Over-Allotment Option
11. Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products
Post Your Comments:
(Date:11/30/2015)... includes an MPP licen c ... , s Solid Drug Nanoparticle (SDN) Technology ; Aims ... through cost cuts of priority ... anywhere in the world will have the right to make, use and distribute lower ... licensees based anywhere in the world will have the right to make, use and ...
(Date:11/30/2015)... Md. , Nov. 30, 2015 ... development company committed to the fostering and monetization ... the current and prospective initiatives designed to create ... Chief Executive Officer of Spherix. "Based on published ... future licensees exceeds $50 billion and Spherix will ...
(Date:11/30/2015)... 2015 TapImmune, Inc. (TPIV), ... innovative peptide and gene-based immunotherapeutics and vaccines for the ... will be presenting at the 8 th Annual ... 2.30 PM PT. Dr. John N. Bonfiglio ... giving the presentation and will join TapImmune management in ...
(Date:11/30/2015)... Germany , November 30, 2015 ... Vienna, Austria to be held December ... (ECNR) in Vienna, Austria to ... wholly owned subsidiary of Vycor Medical, Inc. ("Vycor") (OTCQB: VYCO), ... NovaVision Therapy Suite at the 3rd European Congress of ...
Breaking Biology Technology:
(Date:11/19/2015)... Nov. 19, 2015  Although some 350 companies are ... by a few companies, according to Kalorama Information. These include ... of the market share of the 6.1 billion-dollar molecular ... World Market for Molecular Diagnostic s .    ... is still controlled by one company and only a ...
(Date:11/17/2015)... PARIS , November 17, 2015 ... 17 au 19 novembre  2015.  --> Paris ... 2015.  --> DERMALOG, le leader de l,innovation ... à la fois passeports et empreintes sur la même ... pour les passeports et l,autre pour les empreintes digitales. ...
(Date:11/12/2015)... golden retriever that stayed healthy despite having the gene ... new lead for treating this muscle-wasting disorder, report scientists ... and Harvard and the University of São Paolo in ... pinpoints a protective gene that boosts muscle regeneration, ... Children,s lab of Lou Kunkel , PhD, is ...
Breaking Biology News(10 mins):